Condition: Non Small Cell Lung Cancer · Sponsor: Guangdong Association of Clinical Trials
EGFR-mutated advanced NSCLC patients without ctDNA clearance after lead-in osimertinib monotherapy have inferior PFS compared with those with ctDNA clearance. Consequently, these patients might need an intensified therapeutic strategy, such as osimertinib combined with chemotherapy or ADC. This study aims to explore the efficacy and safety of osimertinib in combination with sacituzumab tirumotecan adaptively in EGFR-mutated advanced NSCLC patients with positive ctDNA after lead-in osimertinib monotherapy.
This description comes directly from the study's public registry record.
Qing Zhou · +51221 862083827812 · gzzhouqing@126.com
Yi-Chen Zhang · +51221 862083827812
Always discuss trial participation with your own doctor first.
| Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University | Guangzhou, Guangdong, China | Recruiting |
| Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences | Meizhou, Guangdong, China | Recruiting |
| The First Affiliated Hospital of Shantou University Medical College | Shantou, Guangdong, China | Recruiting |
| Peking University Shenzhen Hospital | Shenzhen, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07375316